{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:52Z","timestamp":1791588412271,"version":"4.3.4"},"reference-count":26,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among patients with von Willebrand disease (VWD) who are unresponsive to desmopressin therapy, replacement with plasma-derived concentrates is the treatment of choice. Because prospective studies are lacking, such treatment has been largely empirical. A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII\/von Willebrand factor (FVIII\/VWF) concentrate for treatment of bleeding and surgical prophylaxis. Two preparations of the concentrate\u2014one virally inactivated with solvent detergent, the other with an additional heat-treatment step\u2014were evaluated. Pharmacokinetic parameters were similar for both preparations. Using pre-established dosages based on the results of pharmacokinetic studies, 53 patients were administered either preparation for the treatment of 87 bleeding episodes, and 39 patients were treated prophylactically for 71 surgical or invasive procedures. Sixty-five (74.7%) and 10 (11.5%) of the bleeding episodes were controlled with 1 or 2 infusions, respectively. Patients with severe type 3 VWD typically required more infusions and higher doses, at shorter time intervals, than did patients with generally milder types 1 and 2. Among patients undergoing surgical procedures, blood loss was lower than that predicted prospectively, and losses exceeding the predicted value did not correlate with the postinfusion skin bleeding time. In conclusion, the concentrate effectively stopped active bleeding and provided adequate hemostasis for surgical or invasive procedures, even in the absence of bleeding time correction.<\/jats:p>","DOI":"10.1182\/blood.v99.2.450","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study"],"prefix":"10.1182","volume":"99","author":[{"given":"Pier M.","family":"Mannucci","sequence":"first","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chediak","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahid","family":"Hanna","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Byrnes","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ledford","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Ewenstein","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastassios D.","family":"Retzios","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Kapelan","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Kessler","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy; Illinois Masonic Medical Center, Chicago; University of Tennessee, Knoxville; University of Miami, FL; Brigham and Women's Hospital, Boston, MA; Alpha Therapeutic Corporation, Los Angeles, CA; George Washington University Medical Center, Washington, DC; and the Alphanate Study Group."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alphanate Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217314408400_B1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand's disease.","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood."},{"key":"2020021217314408400_B2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","article-title":"Prevalence of von Willebrand disease in children: a multiethnic study.","volume":"123","author":"Werner","year":"1993","journal-title":"J Pediatr."},{"key":"2020021217314408400_B3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease.","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost."},{"key":"2020021217314408400_B4","first-page":"869","article-title":"1-Deamino-8-D arginine vasopressin: a new pharmacological approach in the management of hemophilia and von Willebrand disease.","volume":"1","author":"Mannucci","year":"1997","journal-title":"Lancet."},{"key":"2020021217314408400_B5","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"20","author":"Mannucci","year":"1997","journal-title":"Blood."},{"key":"2020021217314408400_B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","article-title":"Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).","volume":"82","author":"Mannucci","year":"1992","journal-title":"Br J Haematol."},{"key":"2020021217314408400_B7","first-page":"193","article-title":"Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease.","volume":"62","author":"Rodeghiero","year":"1992","journal-title":"Vox Sang."},{"key":"2020021217314408400_B8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00320748","article-title":"Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease.","volume":"56","author":"Fukui","year":"1988","journal-title":"Blut."},{"key":"2020021217314408400_B9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2141.1990.tb02654.x","article-title":"Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y).","volume":"75","author":"Pasi","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021217314408400_B10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01836069","article-title":"Pharmacokinetics and hemostatic effect of different factor VIII\/von Willebrand factor concentrates in von Willebrand's disease type III.","volume":"65","author":"Lethagen","year":"1992","journal-title":"Ann Hematol."},{"key":"2020021217314408400_B11","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.","volume":"71","author":"Hanna","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020021217314408400_B12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P\u00ae in von Willebrand disease.","volume":"4(suppl 3)","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217314408400_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x","article-title":"Summary of a workshop on potency and dosage of von Willebrand factor concentrates.","volume":"4(suppl 3)","author":"Chang","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217314408400_B14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease.","volume":"71","author":"Sadler","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020021217314408400_B15","first-page":"279","volume-title":"Nuclear Medicine in Clinical Pediatrics.","author":"Handmaker","year":"1973"},{"key":"2020021217314408400_B16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1656323","article-title":"Recommended protocol for the study of the ex vivo biological effect of virus-inactivated plasma concentrates in patients with von Willebrand disease.","volume":"68","author":"Mannucci","year":"1992","journal-title":"Thromb Haemost."},{"key":"2020021217314408400_B17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0038-1647360","article-title":"A comparative study of three methods for the visualization of von Willebrand factor (VWF) multimers.","volume":"64","author":"Ledford","year":"1990","journal-title":"Thromb Haemost."},{"key":"2020021217314408400_B18","first-page":"17","article-title":"Noncompartmental pharmacokinetics","volume-title":"Biopharmaceutics and Clinical Pharmacokinetics.","author":"Gibaldi","year":"1984"},{"key":"2020021217314408400_B19","first-page":"139","volume-title":"Pharmacokinetic\/Pharmacodynamic Data Analysis: Concepts and Applications.","author":"Gabrielsson","year":"1997","edition":"2nd ed."},{"key":"2020021217314408400_B20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.1990.tb02655.x","article-title":"Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease.","volume":"75","author":"Cumming","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021217314408400_B21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1996.d01-1860.x","article-title":"Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis.","volume":"94","author":"Menache","year":"1996","journal-title":"Br J Haematol."},{"key":"2020021217314408400_B22","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood."},{"key":"2020021217314408400_B23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.2830250106","article-title":"Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor.","volume":"25","author":"Mannucci","year":"1987","journal-title":"Am J Hematol."},{"key":"2020021217314408400_B24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","article-title":"Antibodies to von Willebrand factor in von Willebrand disease.","volume-title":"Inhibitors to coagulation factor in the 1990s.","author":"Mannucci","year":"1995"},{"key":"2020021217314408400_B25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0887-7963(99)80033-9","article-title":"The transfusion-associated transmission of parvovirus B19.","volume":"13","author":"Azzi","year":"1999","journal-title":"Transfus Med Rev."},{"key":"2020021217314408400_B26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis.","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/2\/450\/1679997\/h8020200450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/2\/450\/1679997\/h8020200450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T18:25:24Z","timestamp":1581531924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/2\/450\/53400\/Treatment-of-von-Willebrand-disease-with-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.2.450","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1,15]]}}}